Articles Related to amphotericin B
Assessment of the Efficacy, Safety and Cost-Effectiveness of Micafungin Compared to Caspofungin and Low Dose Liposomal Amphotericin B for the Treatment of Candidaemia and Clinically Diagnosed Invasive Candidiasis: A Retrospective Audit
Despite several studies having highlighted that candidaemia and invasive fungal disease (IFD) are associated with high mortality and increased costs, there are currently few published studies which provide an insight into real-life practice of invasive candidal diseases. In a medium-sized district general hospital in the UK we sought to compare the efficacy, safety and treatment cost of micafungin versus caspofungin and low dose of liposomal amphotericin B (L-AmB) 1mg/kg/day for the treatment of confirmed candidaemia or clinically diagnosed invasive fungal disease (CDIFD). In the present retrospective audit, a total of 126 patients with candidaemia or CDIFD were reviewed from hospital records and 94 were included in our audit.
Treatment of Cerebral Mucormycosis with Prolonged Liposomal Amphotericin B (>1000 days)
Mucormycosis is a rare but invasive and potentially lethal infection caused by ubiquitous fungi of the order Mucorales. The primary mode of infection is inhalation of fungal spores. Rhinocerebral and pulmonary infections are most common, however, other organ systems including the central nervous system can be affected, presumably by occult fungemia. We describe the prolonged treatment course (>1000 days) of a patient with cerebral mucormycosis using liposomal amphotericin B (LAMB). Two different attempts were made to replace LAMB with posaconazole, but each occasion resulted in therapeutic failure. This case represents the longest course of LAMB reported in the literature.
Simultaneous HPLC Assay of Paracetamol and Sulfapyridine as Markers for Estimating Gastrointestinal Transit of Amphotericin B-containing Nanoparticles in Rat Plasma
A simple and sensitive two-step reversed-phase HPLC method was developed and validated for determining amphotericin B, paracetamol and sulfapyridine in rat plasma using piroxicam as internal standard.
Isolated Laryngeal Coccidioidomycosis - A Case Report and Review of the Literature
Coccidioidomycosis involving the larynx is a rare occurrence which seems to present with non-specific upper airway symptoms. The diagnosis is made by tissue biopsy and the treatment is usually fluconazole for 6-12 months depending on the clinical presentation. In unusual presentations of laryngeal problems clinicians should consider Coccidioidomycosis, especially in endemic regions.